Lacticaseibacillus rhamnosus GG Versus Placebo for Eradication of Vancomycin-Resistant Enterococcus faecium in Intestinal Carriers: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Lacticaseibacillus rhamnosus GG Versus Placebo for Eradication of Vancomycin-Resistant Enterococcus faecium in Intestinal Carriers: A Systematic Review and Meta-Analysis

Published:2023-11-19 Issue:11 Volume:11 Page:2804
ISSN:2076-2607
Container-title:Microorganisms
language:en
Short-container-title:Microorganisms

Author:

Rubin Ingrid Maria Cecilia¹^ORCID,Knudsen Maja Johanne Søndergaard¹,Halkjær Sofie Ingdam²^ORCID,Ilsby Christian Schaadt¹^ORCID,Pinholt Mette¹,Petersen Andreas Munk¹²³^ORCID

Affiliation:

1. Department of Clinical Microbiology, Copenhagen University Hospital—Amager and Hvidovre, 2650 Hvidovre, Denmark

2. Gastrounit, Medical Section, Copenhagen University Hospital—Amager and Hvidovre, 2650 Hvidovre, Denmark

3. Department of Clinical Medicine, University of Copenhagen, 1172 Copenhagen, Denmark

Abstract

The aim of this review was to assess the efficacy and safety of Lacticaseibacillus rhamnosus GG (LGG) (previously known as Lactobacillus rhamnosus GG) for the eradication of vancomycin-resistant Enterococcus faecium (VREfm) in colonized carriers. We searched Cochrane Central, EMBASE, and the PubMed Library from inception to 21 August 2023, for randomized controlled trials (RCTs) investigating the effectiveness of LGG for the eradication of gastrointestinal carriage of VREfm. An initial screening was performed followed by a full-text evaluation of the papers. Out of 4076 articles in the original screening, six RCTs (167 participants) were included in the review. All were placebo-controlled RCTs. The meta-analysis was inconclusive with regard to the effect of LGG for clearing VREfm colonization. The overall quality of the evidence was low due to inconsistency and the small number of patients in the trials. We found insufficient evidence to support the use of LGG for the eradication of VREfm in colonized carriers. There is a need for larger RCTs with a standardized formulation and dosage of LGG in future trials.

Publisher

MDPI AG

Subject

Virology,Microbiology (medical),Microbiology

Link

https://www.mdpi.com/2076-2607/11/11/2804/pdf

Reference51 articles.

1. Tackling Antimicrobial Resistance by promoting Antimicrobial stewardship in Medical and Allied Health Professional Curricula;Majumder;Expert Rev. Anti-Infect. Ther.,2020

2. CDC (2019). Antibiotic Resistance Threats in the United States, 2019, U.S. Department of Health and Human Services, Center for Disease control and Prevention.

3. Högberg, L.D., Weist, K., Suetens, C., Griskeviciene, J., Monnet, D., and Heuer, O. (2014). Annual Epidemiological Report 2014. Antimicrobial Resistance and Healthcare-Associated Infections, ECDC.

4. The rise of the Enterococcus: Beyond vancomycin resistance;Arias;Nat. Rev. Microbiol.,2012

5. Kristich, C.J., Rice, L.B., and Arias, C.A. (2014). Enterococcal Infection—Treatment and Antibiotic Resistance, Massachusetts Eye and Ear Infirmary.